Jun 14, 2022 / 04:20PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good morning, everyone. Really pleased to have Moderna here with us. We have Lavina Talukdar, Head of IR. With that, Lavina, I'm going to turn it over to you if you have any opening comments, so we can just jump into Q&A.
Lavina Talukdar - Moderna, Inc. - Senior VP & Head of IR
Thank you, Salveen, for having us here at the conference. And I would actually like to open it up to Q&A.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VPPerfect. So let's just start here with the data that you just presented, the Phase II/III data of the bivalent booster. Just describe that data to us and what your discussions with regulators have been and what the path forward is to getting it on to market.
Lavina Talukdar - Moderna, Inc. - Senior VP & Head of IR
Great question. Thank you for that. So we just showed the Phase II/III data just last week.
Trustpilot
